Clinical Trials

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2020-02-21T15:04:32-05:00July 12th, 2016|Clinical Trials, News, Research|

14th NIH Pediatric and Wildtype GIST Clinic Convenes

If you have a mutation of any of the SDH subunits (a,b,c, or d), the next important question to ask is whether or not it is a germline mutation. (So far, data has indicated that 80% of SDH-deficient tumors are germline). The term "germline" means that the mutation is present in every cell of your body. Germline mutations are hereditary, and can be passed on to your children. For this reason, genetic testing and counseling could be informative for parents, siblings and other family members. If a family member tests positive for the mutation, this does not mean that they will get GIST.

By |2019-11-08T10:25:09-05:00June 23rd, 2016|News, Pediatric GIST|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By |2019-07-03T10:45:21-04:00May 24th, 2016|Clinical Trials, News, Research|

ASCO Recommends Expanding Clinical Trials to Include More Older Adults

A recent call to action from ASCO (American Society of Clinical Oncology) published in the Journal of Clinical Oncology recommends expanding clinical trials to include more older adults. Given that greater than 60% of cancers in [...]

By |2018-11-05T15:21:56-05:00July 23rd, 2015|Advocacy, Clinical Trials, News|
Go to Top